Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

2024 when Raymond James raised their price target to $116. Raymond James previously had an outperform for Viking Therapeutics Inc. Analysts arrive at stock ratings after doing extensive research ...

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly ...

Following the release of its earnings report, Viking Therapeutics' stock price experienced a surge, climbing as much as 0%. This positive market response leaves some investors questioning if ...

Viking Therapeutics (NASDAQ: VKTX) has captured the attention of investors, with its stock price skyrocketing over 400% in one year. This remarkable performance stems from the company's promising ...

Some of VK2735's success could already be baked into the company's stock price, which makes the possibility of anything going wrong even riskier. So, whether Viking Therapeutics is for you ...

On Tuesday, Oppenheimer analysts adjusted their outlook on Viking Therapeutics (NASDAQ: VKTX), reducing the stock’s price target from $164.00 to $100.00, while maintaining an Outperform rating ...

Viking Therapeutics VKTX is ... Those who already own this stock may continue to do so. Multiple catalysts could trigger share price movements, such as pipeline advancements, data from these ...

Viking Therapeutics sports a $7.2 billion market cap at recent prices, but commercial-stage biotech stocks tend to trade at mid-single-digit multiples of annual sales. That means its stock price ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that ...